- Home
- EPIX
EPIX
ESSA Pharma Inc.
as 02-21-2025 4:00pm EST
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer. It is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
| Founded: | 2009 | Country: | Canada |
| Employees: | N/A | City: | VANCOUVER |
| Market Cap: | 76.8M | IPO Year: | N/A |
| Target Price: | $2.00 | AVG Volume (30 days): | 252.4K |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.70 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.40 - $9.92 | Next Earning Date: | 02-11-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest ESSA Pharma Inc. News
EPIX Breaking Stock News: Dive into EPIX Ticker-Specific Updates for Smart Investing
Simply Wall St.
3 days ago
February 2025's Top US Penny Stocks To Consider
Associated Press Finance
11 days ago
ESSA Pharma: Fiscal Q1 Earnings Snapshot
CNW Group
11 days ago
ESSA Pharma Reports Financial Results for Fiscal First Quarter Ended December 31, 2024
Simply Wall St.
2 months ago
3 Promising US Penny Stocks With Market Caps Under $80M
Simply Wall St.
2 months ago
When Will ESSA Pharma Inc. (NASDAQ:EPIX) Turn A Profit?
Associated Press Finance
2 months ago
ESSA Pharma: Fiscal Q4 Earnings Snapshot
CNW Group
2 months ago
ESSA Pharma Provides Corporate Update and Reports Financial Results for Fiscal Fourth Quarter and Year Ended September 30, 2024
Simply Wall St.
3 months ago
ESSA Pharma And 2 Other US Penny Stocks To Watch
Compare EPIX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "EPIX ESSA Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.